
Opinion|Videos|June 11, 2024
PROUD-PV/CONTINUATION-PV Trials for Ropeginterferon Alfa-2b in Polycythemia Vera
This segment discusses the key efficacy and safety considerations from the PROUD-PV and CONTINUATION-PV trials evaluating ropeginterferon alfa-2b as a treatment option for polycythemia vera.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma
2
ASCO 2026 Breast Cancer Highlights: Beyond the LBAs
3
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
4
Phase 3 Trial of Sacituzumab Govitecan Plus Pembrolizumab Stopped Early in First-Line mNSCLC
5



































